Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Completed · Phase 2 · Has a placebo group

Conditions studied: Complicated Intra-abdominal Infection

In brief

This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).

Key facts

Study ID

NCT01265784

Run by

Tetraphase Pharmaceuticals, Inc

People needed

143

Starts

2011-01-01

Expected to finish

2012-05-01

Last updated by the study team

2022-01-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Abdominal pain/discomfort with onset prior to hospitalization
• Evidence of a systemic inflammatory response
• Physical findings consistent with intra-abdominal infection (IAI)
• Clinical diagnosis of community-acquired IAI requiring urgent surgical or percutaneous intervention and not expected to require antibacterial therapy for longer than 14 days
• Body mass index (BMI) of ≤ 30 kilograms per square meter (kg/m\^2)
• Able to provide informed consent. If the participant is unable to provide informed consent, the participant's legally acceptable representative may provide written consent in accordance with institutional guidelines
• If female, not pregnant or nursing or, if of child-bearing potential either: will commit to use at least two medically accepted, effective methods of birth control (for example, condom, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring) during study drug dosing and for 90 days following last study drug dose or practicing sexual abstinence

You may not qualify if…

• Symptoms related to diagnosis of complicated appendicitis (if current diagnosis) for < 24 hours prior to current hospitalization
• Previously hospitalized or admitted to a healthcare facility within the last 6 months
• Managed by Staged Abdominal Repair or other open abdomen technique
• Known at study entry to have an IAI caused by a pathogen(s) resistant to both study drug antibiotics
• Acute Physiology and Chronic Health Evaluation (APACHE) II score > 25
• Unlikely to survive the 6-8 week study period
• Any rapidly-progressing disease or immediately life-threatening illness, including acute hepatic failure, respiratory failure and septic shock
• Requirement for vasopressors at therapeutic dosages
• Renal failure
• Presence or possible signs of hepatic disease
• Hematocrit < 25% or hemoglobin < 8 grams per deciliter (g/dL)
• Neutropenia with absolute neutrophil count < 1000 cells per cubic millimeter (mm\^3)
• Platelet count < 50,000/mm3
• Abnormal coagulation tests or participant on anticoagulants
• Immunocompromised condition, including known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS), organ (bone marrow) transplant recipients, and hematological malignancy. Immunosuppressive therapy, including use of high-dose corticosteroids (for example, > 40 milligrams [mg] prednisone or equivalent per day for greater than 2 weeks)
• History of hypersensitivity reactions to tetracyclines or carbapenems
• Participation in any investigational drug or device study within 30 days prior to study entry
• Known or suspected central nervous system (CNS) disorder that may predispose to seizures or lower seizure threshold
• Previously received TP-434 in a clinical trial
• More than 24 hours duration of systemic antibiotic coverage for current condition
• Received ertapenem or any other carbapenem, or tigecycline for the current infection
• Need for concomitant systemic antimicrobial agents other than study drug or received systemic (IV or oral) antibiotics in the last 3 months
• Refusal of mechanical ventilation, dialysis or hemofiltration, cardioversion or any other resuscitative measures and drug/fluid therapy at time of consent
• Known or suspected inflammatory bowel disease or associated visceral abscess

Where it is running

• Long Beach VA Medical Center — Long Beach, California, United States
• Denver Health Medical Center — Denver, Colorado, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Barnes Jewish Hospital — St Louis, Missouri, United States
• Mercury Street Medical Group — Butte, Montana, United States
• MHAT "Yulia Vrevska - Byala" EOOD, Byala — Byala, Bulgaria
• UMHAT "Dr. Georgi Stranski" EAD, Pleven — Pleven, Bulgaria
• UMHAT "Sveti Georgi" EAD, Plovdiv — Plovdiv, Bulgaria
• MHAT "Russe" AD, Russe — Rousse, Bulgaria
• MHAT "Tokuda Hospital Sofia" AD, Sofia — Sofia, Bulgaria
• UMHAT "Tzaritza Yoanna" EAD, Sofia — Sofia, Bulgaria
• UMHATEM "N.I. Pirogov" EAD, Sofia — Sofia, Bulgaria
• UMHATEM "N.I.Pirogov" EAD, Sofia — Sofia, Bulgaria
• Bangalore Medical College and Research Institute, Victoria Hospital — Fort Mumbai, Bangalore, India
• Amrita Institute of Medical Sciences and Research Centre — Kochi, Kerala, India
• Sahyadri Munot Hospital — Pune, Maharashtra, India
• S.R. Kalla Memorial Gastro & General Hospital — Jaipur, Rajasthan, India
• HCG-Medisurge Hospitals Pvt. Ltd. — Ahmedabad, India
• Santosh Hospital — Bangalore, India
• K.R. Hospital — Bangalore, India
• M.S. Ramalah Medical College and Hospitals — Bangalore, India
• Sai Vani Hospitals, Ltd. — Hyderabad, India
• Daugavpils Regional Hospital — Daugavpils, Latvia
• Jekabpils Regional Hospital — Jēkabpils, Latvia
• Rezeknes Hospital — Rēzekne, Latvia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.